Exploiting differences in caspase-2 and-3 S2 subsites for selectivity: Structure-based design, solid-phase synthesis and in vitro activity of novel substrate-based caspase-2 inhibitors

被引:32
作者
Maillard, Michel C. [1 ]
Brookfield, Frederick A. [2 ]
Courtney, Stephen M. [2 ]
Eustache, Florence M. [2 ]
Gemkow, Mark J. [3 ]
Handel, Rebecca K. [2 ]
Johnson, Laura C. [2 ]
Johnson, Peter D. [2 ]
Kerry, Mark A. [2 ]
Krieger, Florian [3 ]
Meniconi, Mirco [2 ]
Munoz-Sanjuan, Ignacio [1 ]
Palfrey, Jordan J. [2 ]
Park, Hyunsun [1 ]
Schaertl, Sabine [3 ]
Taylor, Malcolm G. [2 ]
Weddell, Derek [2 ]
Dominguez, Celia [1 ]
机构
[1] CHDI Management Inc, Los Angeles, CA 90045 USA
[2] Evotec UK Ltd, Abingdon OX14 4SA, Oxon, England
[3] Evotec AG, Hamburg, Germany
关键词
Caspase inhibitors; Huntington's disease; Proline-derived P-2 scaffolds; HUNTINGTONS-DISEASE; CONVERTING-ENZYME; SPECIFICITY; CLEAVAGE; ACTIVATION; PROTEIN; POTENT; IDENTIFICATION; FAMILY; MODEL;
D O I
10.1016/j.bmc.2011.08.020
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Several caspases have been implicated in the pathogenesis of Huntington's disease (HD); however, existing caspase inhibitors lack the selectivity required to investigate the specific involvement of individual caspases in the neuronal cell death associated with HD. In order to explore the potential role played by caspase-2, the potent but non-selective canonical Ac-VDVAD-CHO caspase-2 inhibitor 1 was rationally modified at the P-2 residue in an attempt to decrease its activity against caspase-3. With the aid of structural information on the caspase-2, and -3 active sites and molecular modeling, a 3-(S)-substituted-L-proline along with four additional scaffold variants were selected as P-2 elements for their predicted ability to clash sterically with a residue of the caspase-3 S-2 pocket. These elements were then incorporated by solid-phase synthesis into pentapeptide aldehydes 33a-v. Proline-based compound 33h bearing a bulky 3-(S)-substituent displayed advantageous characteristics in biochemical and cellular assays with 20- to 60-fold increased selectivity for caspase-2 and similar to 200-fold decreased caspase-3 potency compared to the reference inhibitor 1. Further optimization of this prototype compound may lead to the discovery of valuable pharmacological tools for the study of caspase-2 mediated cell death, particularly as it relates to HD. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:5833 / 5851
页数:19
相关论文
共 57 条
[1]   Plasticity of S2-S4 specificity pockets of executioner caspase-7 revealed by structural and kinetic analysis [J].
Agniswamy, Johnson ;
Fang, Bin ;
Weber, Irene T. .
FEBS JOURNAL, 2007, 274 (18) :4752-4765
[2]   A cell-based screen for drugs to treat Huntington's disease [J].
Aiken, CT ;
Tobin, AJ ;
Schweitzer, ES .
NEUROBIOLOGY OF DISEASE, 2004, 16 (03) :546-555
[3]  
[Anonymous], PYMOL MOL GRAPH SYST
[4]  
[Anonymous], MOE 2009 10
[5]   Evaluation of recombinant caspase specificity by competitive substrates [J].
Benkova, Bistra ;
Lozanov, Valentin ;
Ivanov, Ivaylo P. ;
Mitev, Vanio .
ANALYTICAL BIOCHEMISTRY, 2009, 394 (01) :68-74
[6]   Commonly used caspase inhibitors designed based on substrate specificity profiles lack selectivity [J].
Berger, Alicia B. ;
Sexton, Kelly B. ;
Bogyo, Matthew .
CELL RESEARCH, 2006, 16 (12) :961-963
[7]   Identification of early intermediates of caspase activation using selective inhibitors and activity-based probes [J].
Berger, Alicia B. ;
Witte, Martin D. ;
Denault, Jean-Bernard ;
Sadaghiani, Amir Masoud ;
Sexton, Kelly M. B. ;
Salvesen, Guy S. ;
Bogyo, Matthew .
MOLECULAR CELL, 2006, 23 (04) :509-521
[8]  
Black C., 2001, [No title captured], Patent No. [WO/2001/27085, 200127085]
[9]   An asymmetric dihydroxylation route to (2S,3S)-3-hydroxypipecolic acid [J].
Bodas, MS ;
Kumar, P .
TETRAHEDRON LETTERS, 2004, 45 (46) :8461-8463
[10]  
Chauvier D., 2006, [No title captured], Patent No. [WO/2006/056487, 2006056487]